Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new pharmacological alternative for the treatment of diabetes. Aim: To report our experience with the use of this type of drugs in type 2 diabetics treated in an outpatient clinic. Material and Methods: We selected 77 type 2 dia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Contreras,Álvaro, Grassi,Bruno, Alfaro,Daniela, González,Felipe, Ortega,Valeska
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2019
Materias:	Albuminuria Diabetes Mellitus Type 2 Hypoglycemic Agents Sodium-Glucose Transporter 2 Inhibitors
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000901093
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872019000901093
record_format	dspace
spelling	oai:scielo:S0034-988720190009010932020-01-07Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2Contreras,ÁlvaroGrassi,BrunoAlfaro,DanielaGonzález,FelipeOrtega,Valeska Albuminuria Diabetes Mellitus Type 2 Hypoglycemic Agents Sodium-Glucose Transporter 2 Inhibitors Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new pharmacological alternative for the treatment of diabetes. Aim: To report our experience with the use of this type of drugs in type 2 diabetics treated in an outpatient clinic. Material and Methods: We selected 77 type 2 diabetic patients aged 59 ± 11 years (45 men) who started SGLT2i, based on the advice of their treating physician. We registered their demographic characteristics and changes in metabolic parameters, weight, blood pressure, albuminuria and adverse effects, during a follow-up of at least three months. Results: We observed a decrease of glycosylated hemoglobin A1c of 0.8 ± 1.14% (p < 0.01) and a weight decrease of 2.5 ± 2.24 kg (p < 0.01). The proportion of patients with a glycosylated hemoglobin A1c of less than 7% increased from 7.2% to 30.9% (p = 0.002). In addition, a relative decrease in albuminuria of 39.9% was observed (p = 0.07). The treatment was well tolerated with a rate of adverse effects of 21%, all of them being categorized as mild. Of these, most of them corresponded to genital mycotic infections. Conclusions: The effects observed in this study are comparable and of similar magnitude to randomized studies of SGLT2i reported in the international literature.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.147 n.9 20192019-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000901093es10.4067/s0034-98872019000901093
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Albuminuria Diabetes Mellitus Type 2 Hypoglycemic Agents Sodium-Glucose Transporter 2 Inhibitors
spellingShingle	Albuminuria Diabetes Mellitus Type 2 Hypoglycemic Agents Sodium-Glucose Transporter 2 Inhibitors Contreras,Álvaro Grassi,Bruno Alfaro,Daniela González,Felipe Ortega,Valeska Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
description	Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new pharmacological alternative for the treatment of diabetes. Aim: To report our experience with the use of this type of drugs in type 2 diabetics treated in an outpatient clinic. Material and Methods: We selected 77 type 2 diabetic patients aged 59 ± 11 years (45 men) who started SGLT2i, based on the advice of their treating physician. We registered their demographic characteristics and changes in metabolic parameters, weight, blood pressure, albuminuria and adverse effects, during a follow-up of at least three months. Results: We observed a decrease of glycosylated hemoglobin A1c of 0.8 ± 1.14% (p < 0.01) and a weight decrease of 2.5 ± 2.24 kg (p < 0.01). The proportion of patients with a glycosylated hemoglobin A1c of less than 7% increased from 7.2% to 30.9% (p = 0.002). In addition, a relative decrease in albuminuria of 39.9% was observed (p = 0.07). The treatment was well tolerated with a rate of adverse effects of 21%, all of them being categorized as mild. Of these, most of them corresponded to genital mycotic infections. Conclusions: The effects observed in this study are comparable and of similar magnitude to randomized studies of SGLT2i reported in the international literature.
author	Contreras,Álvaro Grassi,Bruno Alfaro,Daniela González,Felipe Ortega,Valeska
author_facet	Contreras,Álvaro Grassi,Bruno Alfaro,Daniela González,Felipe Ortega,Valeska
author_sort	Contreras,Álvaro
title	Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
title_short	Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
title_full	Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
title_fullStr	Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
title_full_unstemmed	Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
title_sort	experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
publisher	Sociedad Médica de Santiago
publishDate	2019
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000901093
work_keys_str_mv	AT contrerasalvaro experienciadeusodeinhibidoresdelcotransportadorsodioglucosa2endiabeticostipo2 AT grassibruno experienciadeusodeinhibidoresdelcotransportadorsodioglucosa2endiabeticostipo2 AT alfarodaniela experienciadeusodeinhibidoresdelcotransportadorsodioglucosa2endiabeticostipo2 AT gonzalezfelipe experienciadeusodeinhibidoresdelcotransportadorsodioglucosa2endiabeticostipo2 AT ortegavaleska experienciadeusodeinhibidoresdelcotransportadorsodioglucosa2endiabeticostipo2
_version_	1718437081094553600

Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2

Ejemplares similares